DEVELOPMENT OF A NONTOXIC MULTIMODALITY CONTRAST AGENT

癌症是世界上主要的死亡原因之一。 现在有 已经开发出许多替代治疗方法并显示出前景。 成功的治疗通常取决于早期诊断。虽然 肿瘤与正常组织在病理学上不同， 总的物理性质的差异，直到它成为 显而易见 因此，三大医疗模式没有 在识别小肿瘤方面取得了预期的成功。程序 成本不断增加。 这项建议涉及发展 一种低成本的药物通过静脉注射， 血管壁中的大量，并可以作为造影剂的所有 三种主要模式，超声、X射线和MR成像。 我们的生产 方法和材料成本将提供低成本的诊断剂。 微粒体提出扩展其现有的明胶微泡技术 涉及其中含有X射线的小的充气明胶微粒， 磁共振成像剂。 建议的阶段活动包括创建8个 微米颗粒和建立浓度水平。 II期研究 将倾向于将颗粒尺寸减小到小于3微米， 证明了其在动物模型和有限的临床病例中的功效。

Cancer is one of the leading causes of death in the world. There are now many alternative treatments which have been developed and show promise. Successful treatment generally depends upon early diagnosis. Although tumors differ from normal tissue pathologically there are no significant differences in gross physical properties up to the point when it becomes palpable. Therefore the three major medical modalities have not demonstrated anticipated success in identifying small tumors. Procedural costs are continually increasing. This proposal concerns the development of a low-cost agent delivered via venous injection which adheres to tumor vessel walls in large numbers and can act as a contrast agent for all three major modalities, Ultrasound, X-ray and MR Imaging. Our production method and material costs will provide low cost diagnostic agents. Microsome proposes to extend its existing gelatin microbubble technology to small air-filled gelatin microparticles containing therein an X-ray and an MR Imaging agent. The proposed Phase activity consists of creating 8 micron particles and establishing concentration levels. Phase II studies would be oriented toward reducing particle size to less than 3 microns and demonstrating its efficacy in animal models and limited clinical cases.